Satri-cel study marks first randomized CAR T-cell success in solid tumors

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously treated gastric or gastro-esophageal junction cancer, according to a multicenter randomized trial led by Peking University Cancer Hospital in China.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup